Caribou Q3 net loss $26.6M, cash $342.6M; CB-011 IND submitted, CB-010 ODD for FL

Caribou Biosciences, Inc.

2022-Q3 EPS reported -$1.19 revenue$10,159,000

Net loss $26.6M vs $21.0M YoY; revenue $3.3M (down from $4.0M) on lower AbbVie collaboration revenue.
Cash, cash equivalents, and marketable securities $342.6M as of Sept 30, 2022, down from $413.5M at Dec 31, 2021.
CB-010 ANTLER Phase 1 trial enrolling at dose level 2; ODD for follicular lymphoma granted Sept 2022.
CB-011 IND for relapsed/refractory multiple myeloma submitted to FDA in Q4 2022; FDA response expected by YE 2022.
CB-012 IND for r/r AML expected in 2023; CB-020 target selection for CAR-NK solid tumors expected Q4 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Caribou Biosciences, Inc. reported the third quarter of 2022 results: revenue $3.3 million, net income $26.6 million.

Period: the third quarter of 2022
Revenue: $3.3 million
Net income: $26.6 million
Result: reported results

Exact text from the filing

of September 30, 2022, compared to $413.5 million as of December 31, 2021. Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $3.3 million for the three months ended September 30, 2022, compared to $4.0 million for the same period in 2021. The decrease was primarily due to a decrease in revenue under the AbbVie

View on SEC.gov

Browse all earnings releases →

Caribou Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001619856-22-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.